% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Goeppert:126600,
      author       = {B. Goeppert and L. Frauenschuh and M. Zucknick$^*$ and S.
                      Roessler and A. Mehrabi and M. Hafezi and A. Stenzinger and
                      A. Warth and A. Pathil and M. Renner and P. Schirmacher and
                      W. Weichert$^*$},
      title        = {{M}ajor histocompatibility complex class {I} expression
                      impacts on patient survival and type and density of immune
                      cells in biliary tract cancer.},
      journal      = {British journal of cancer},
      volume       = {113},
      number       = {9},
      issn         = {1532-1827},
      address      = {Edinburgh},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2017-02628},
      pages        = {1343 - 1349},
      year         = {2015},
      abstract     = {Biliary tract cancers (BTC) are rare malignant tumours with
                      a poor prognosis. Previously, we have presented a detailed
                      characterisation of the inflammatory infiltrate in BTC.
                      Here, we analysed the impact of the expression of major
                      histocompatibility complex class I (MHC I) on patient
                      survival and the quantity, as well as the quality of
                      tumour-infiltrating immune cell types in BTC.MHC I
                      expression was assessed semi-quantitatively in 334 BTC,
                      including extrahepatic (n=129) and intrahepatic
                      cholangiocarcinomas (n=146), as well as adenocarcinomas of
                      the gallbladder (n=59). In addition, 71 high-grade biliary
                      intraepithelial lesions (BilIN 3) were included. Results
                      were correlated with data on antitumour inflammation and
                      investigated with respect to their association with
                      clinicopathological variables and patient survival.BTC
                      showed a wide spectrum of different MHC I expression
                      patterns ranging from complete negativity in some tumours to
                      strong homogenous expression in others. In BilIN 3,
                      significantly higher MHC I expression levels were seen
                      compared to invasive tumours (P=0.004). Patients with strong
                      tumoural MHC I expression had a significantly higher overall
                      survival probability (median survival benefit: 8 months;
                      P=0.006). MHC I expression strongly correlated with the
                      number of tumour-infiltrating T-lymphocytes (CD4(+) and
                      CD8(+)) and macrophages.Differences of MHC I expression
                      predict patient outcome and show correlations with specific
                      components of the inflammatory infiltrate in BTC. These
                      findings contribute to a better understanding of immune
                      response and immune escape phenomena in
                      cholangiocarcinogenesis.},
      keywords     = {Histocompatibility Antigens Class I (NLM Chemicals)},
      cin          = {C060 / L701 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)L701-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26461054},
      pmc          = {pmc:PMC4815783},
      doi          = {10.1038/bjc.2015.337},
      url          = {https://inrepo02.dkfz.de/record/126600},
}